{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:00:25Z","timestamp":1784930425587,"version":"3.55.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>\n                    Acute promyelocytic leukemia (APL) is a highly curable form of acute myeloid leukemia (AML) when treated early with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Resource constraints in low- and middle-income countries (LMICs) may affect results. This study examined the clinical characteristics and outcomes of pediatric patients with APL receiving an ATRA-ATO-based regimen. The retrospective review included 1- to 16-year-olds diagnosed between January 2019 and December 2022. Morphology and PML-RARA detection by fluorescence in situ hybridization (FISH) confirmed the diagnosis. Patients were stratified by initial white cell count (WCC) (low-risk &lt;10\u00d710\n                    <jats:sup>9<\/jats:sup>\n                    \/L; high-risk \u226510\u00d710\n                    <jats:sup>9<\/jats:sup>\n                    \/L). Data were retrieved from electronic medical records. Event-free survival (EFS) rates were obtained using the Kaplan-Meier analysis. Fifty patients (mean age: 10.7\u00a0y; 56% male) were evaluated. Low-risk was 32%, and high-risk was 68%. Thrombocytopenia and hypofibrinogenemia were common. All patients had PML-RARA FISH-positives, and 100% of evaluated patients attained morphologic and molecular remissions. Eleven (22%) patients died, mostly from hemorrhage. Abandonment and relapses were observed in 10% and 8% of patients, respectively. Two-year EFS was 60% (low-risk 81%; high-risk 50%). The ATRA-ATO regimen showed substantial remission rates, but early deaths remain a concern. Increased survival rates in resource-constrained environments require improved early detection, referral, and supportive care.\n                  <\/jats:p>","DOI":"10.1097\/mph.0000000000003231","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T16:00:10Z","timestamp":1781539210000},"page":"277-282","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Presentation and Treatment Outcomes of Pediatric Acute Promyelocytic Leukemia: A Study From a Developing Country"],"prefix":"10.1097","volume":"48","author":[{"given":"Naila","family":"Rafiq","sequence":"first","affiliation":[{"name":"Pediatric Hematology Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam Q.","family":"Pathan","sequence":"additional","affiliation":[{"name":"Pediatric Hematology Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadia","family":"Muhammad","sequence":"additional","affiliation":[{"name":"Pediatric Hematology Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelum","family":"Mansoor","sequence":"additional","affiliation":[{"name":"Hematology, Indus Hospital and Health Network, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"R1-20260724","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11912-009-0060-0","article-title":"Acute promyelocytic leukemia in childhood","volume":"11","author":"Gregory","year":"2009","journal-title":"Curr Oncol Rep"},{"key":"R2-20260724","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000365117","article-title":"Acute promyelocytic leukemia in children and adolescents","volume":"132","author":"Stein","year":"2014","journal-title":"Acta Haematol"},{"key":"R3-20260724","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/16078454.2021.1882146","article-title":"Ethnic differences in acute promyelocytic leukaemia between New Zealand Polynesian and European patients","volume":"26","author":"Varghese","year":"2021","journal-title":"Hematology"},{"key":"R4-20260724","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood.V93.10.3167.410k44_3167_3215","article-title":"Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia","volume":"93","author":"Melnick","year":"1999","journal-title":"Blood"},{"key":"R5-20260724","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1053\/j.seminoncol.2008.04.010","article-title":"Acute promyelocytic leukemia: recent advances in diagnosis and management","volume":"35","author":"Lo-Coco","year":"2008","journal-title":"Semin Oncol"},{"key":"R6-20260724","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1038\/sj.leu.2402720","article-title":"Variations on a theme: the alternate translocations in APL","volume":"16","author":"Redner","year":"2002","journal-title":"Leukemia"},{"key":"R7-20260724","doi-asserted-by":"crossref","first-page":"5328","DOI":"10.1073\/pnas.0400053101","article-title":"All-trans retinoic acid\/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia","volume":"101","author":"Shen","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R8-20260724","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2141.2011.08922.x","article-title":"The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia","volume":"156","author":"Breen","year":"2011","journal-title":"Br J Haematol"},{"key":"R9-20260724","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1182\/blood-2007-07-102798","article-title":"Acute promyelocytic leukemia: from highly fatal to highly curable","volume":"111","author":"Wang","year":"2008","journal-title":"Blood"},{"key":"R10-20260724","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N Engl J Med"},{"key":"R11-20260724","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1200\/JCO.2011.38.4560","article-title":"Outcome of acute promyelocytic leukemia in children and adolescents: an analysis in two consecutive trials of the European APL Group","volume":"30","author":"Bally","year":"2012","journal-title":"J Clin Oncol"},{"key":"R12-20260724","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1182\/blood-2004-05-1971","article-title":"GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children","volume":"106","author":"Testi","year":"2005","journal-title":"Blood"},{"key":"R13-20260724","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1751-7133.2011.00278.x","article-title":"Subclinical anthracycline cardiotoxicity in patients with acute promyelocytic leukemia in long-term remission after the AIDA protocol","volume":"18","author":"Pellicori","year":"2012","journal-title":"Congest Heart Fail"},{"key":"R14-20260724","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2141.2010.08107.x","article-title":"Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses: report from the AML-BFM Study Group","volume":"149","author":"Creutzig","year":"2010","journal-title":"Br J Haematol"},{"key":"R15-20260724","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2012-02-410746","article-title":"All-trans-retinoic acid, idarubicin, and intravenous arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)","volume":"120","author":"Iland","year":"2012","journal-title":"Blood"},{"key":"R16-20260724","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1200\/JCO.20.03096","article-title":"Arsenic combined with all-trans retinoic acid for pediatric acute promyelocytic leukemia: report from the CCLG-APL2016 protocol study","volume":"39","author":"Zheng","year":"2021","journal-title":"J Clin Oncol"},{"key":"R17-20260724","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3390\/ijms22020642","article-title":"Acute promyelocytic leukemia in children: a model of precision medicine and chemotherapy-free therapy","volume":"22","author":"Gurnari","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R18-20260724","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.htct.2024.05.002","article-title":"Diagnosis and management of acute promyelocytic leukemia: Brazilian consensus guidelines 2024 on behalf of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy","volume":"46","author":"de Figueiredo-Pontes","year":"2024","journal-title":"Hematol Transfus Cell Ther"},{"key":"R19-20260724","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.leukres.2013.04.009","article-title":"Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia","volume":"37","author":"Trifilio","year":"2013","journal-title":"Leukemia Res"},{"key":"R20-20260724","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamaoncol.2021.5206","article-title":"Trans retinoic acid for the treatment of pediatric acute promyelocytic leukemia a report from the Children\u2019s Oncology Group AAML1331 trial","volume":"8","author":"Kutny","year":"2022","journal-title":"JAMA Oncol"},{"key":"R21-20260724","doi-asserted-by":"crossref","first-page":"e26867","DOI":"10.1002\/pbc.26867","article-title":"The duration of anthracycline infusion should be at least one hour in children with cancer: a clinical practice guideline","volume":"65","author":"Loeffen","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"R22-20260724","first-page":"162","article-title":"Management of APL in developing countries: epidemiology, challenges, and opportunities for international collaboration","volume":"1","author":"Ribeiro","year":"2006","journal-title":"ASH Edu Program Book"},{"key":"R23-20260724","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3892\/etm.2012.546","article-title":"Retrospective analysis of 119 cases of pediatric acute promyelocyticleukemia: comparisons of four treatment regimes","volume":"4","author":"Li","year":"2012","journal-title":"ExpTher Med"},{"key":"R24-20260724","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1080\/10245332.2017.1412380","article-title":"Clinical characteristics and outcome of childhood acute promyelocitic leukemia (APL) in Saudi Arabia: a multicenter SAPHOS leukemia group study","volume":"23","author":"Jastaniah","year":"2018","journal-title":"Hematology"},{"key":"R25-20260724","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/leu.2017.71","article-title":"Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry","volume":"31","author":"Lehmann","year":"2017","journal-title":"Leukemia"},{"key":"R26-20260724","doi-asserted-by":"crossref","first-page":"e0163090","DOI":"10.1371\/journal.pone.0163090","article-title":"Determinants of treatment abandonment in childhood cancer: results from a global survey","volume":"11","author":"Friedrich","year":"2016","journal-title":"PLoS One"},{"key":"R27-20260724","doi-asserted-by":"crossref","first-page":"e26560","DOI":"10.1002\/pbc.26560","article-title":"Improvement in treatment abandonment in pediatric patients with cancer in Guatemala","volume":"64","author":"Alvarez","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"R28-20260724","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s12288-021-01404-1","article-title":"An outcome analysis of childhood acute promyelocytic leukemia treated with atra and arsenic trioxide, and limited dose anthracycline","volume":"37","author":"Jabbar","year":"2021","journal-title":"Indian J Hematol Blood Transfus"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T21:00:23Z","timestamp":1784926823000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000003231","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"2025-08-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}